Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

FOLD

Amicus Therapeutics Inc

Nov 27 • 04:00PM ET

9.96

Dollar change +0.09
Percentage change 0.91	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI VB IWM VBK XBI VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	2.55%	Shs Outstand	293.59M	Perf Week	3.86%
Market Cap	3.00B	Forward P/E	68.31	EPS next Y	0.15	Insider Trans	-0.69%	Shs Float	291.20M	Perf Month	-13.32%
Income	-104.69M	PEG	-	EPS next Q	0.02	Inst Own	102.66%	Short Float	7.21%	Perf Quarter	-11.86%
Sales	493.67M	P/S	6.08	EPS this Y	60.93%	Inst Trans	-2.77%	Short Ratio	8.83	Perf Half Y	0.81%
Book/sh	0.60	P/B	16.64	EPS next Y	173.18%	ROA	-13.50%	Short Interest	21.00M	Perf Year	-5.86%
Cash/sh	0.83	P/C	12.02	EPS next 5Y	-	ROE	-67.09%	52W Range	9.02 - 14.57	Perf YTD	-29.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.84%	ROI	-17.02%	52W High	-31.64%	Beta	0.60
Dividend TTM	-	Quick Ratio	2.42	Sales past 5Y	37.81%	Gross Margin	88.23%	52W Low	10.42%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	3.15	EPS Y/Y TTM	41.95%	Oper. Margin	2.92%	RSI (14)	40.57	Volatility	2.93% 4.03%
Employees	517	Debt/Eq	2.49	Sales Y/Y TTM	32.58%	Profit Margin	-21.21%	Recom	1.31	Target Price	17.75
Option/Short	Yes / Yes	LT Debt/Eq	2.44	EPS Q/Q	69.73%	Payout	-	Rel Volume	0.50	Prev Close	9.87
Sales Surprise	4.88%	EPS Surprise	-1766.67%	Sales Q/Q	36.73%	Earnings	Nov 06 BMO	Avg Volume	2.38M	Price	9.96
SMA20	-4.22%	SMA50	-7.35%	SMA200	-8.76%	Trades		Volume	1,193,232	Change	0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17
Mar-02-21	Initiated	Stifel	Hold	$13
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral	$19
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$30 → $17
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight	$20 → $30
Dec-10-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy	$19

Show Previous Ratings

Nov-07-24 09:50AM	Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock (Zacks)
02:09AM	Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:26AM	Q3 2024 Amicus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:30PM	Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings (Zacks)
08:25AM	Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:22AM	Loading…
07:22AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-04-24 09:55AM	Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know (Zacks)
Nov-01-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 (GlobeNewswire)
Oct-30-24 10:01AM	Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-28-24 07:00AM	Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-21-24 09:50AM	Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term (Zacks)
Oct-18-24 12:20PM	Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? (Zacks)
09:55AM	How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% (Zacks)
09:55AM	Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
06:41AM	Loading…
06:41AM	Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? (Zacks)
Oct-17-24 11:07AM	Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug (Benzinga) +14.00%
07:00AM	Amicus Therapeutics Announces Settlement of Galafold (migalastat) Patent Litigation with Teva (GlobeNewswire)
Oct-09-24 05:35PM	Amicus Therapeutics Inc (FOLD) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Oct-07-24 05:02PM	JPMorgan Chase & Co's Strategic Reduction in Amicus Therapeutics Inc (GuruFocus.com)
Oct-04-24 07:00AM	Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 (GlobeNewswire)
Sep-24-24 11:50PM	Is Amicus Therapeutics, Inc. (FOLD) the Best Guru Stock To Buy Now? (Insider Monkey)
Sep-03-24 07:46AM	UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
07:05AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
07:00AM	Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium (GlobeNewswire)
Aug-30-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
Aug-21-24 11:24AM	Amicus (FOLD) Banks on Galafold, High Dependence a Concern (Zacks)
Aug-09-24 10:31AM	Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated (Zacks)
Aug-08-24 09:00PM	Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +13.20%
08:25AM	Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates (Zacks)
07:22AM	Loading…
07:22AM	Amicus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Jul-30-24 07:00AM	Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-26-24 09:47AM	Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? (Zacks)
Jun-05-24 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 07:00AM	Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) as Best Pharmaceutical Product (GlobeNewswire)
May-24-24 08:30AM	Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? (Zacks)
May-14-24 07:15AM	Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target (MT Newswires)
May-10-24 04:03PM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:10PM	Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ... (GuruFocus.com)
11:33AM	UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating (MT Newswires)
10:46AM	Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated (Zacks)
May-09-24 10:30PM	Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -6.51%
11:56AM	FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:26AM	Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise (MT Newswires)
08:25AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:21AM	Amicus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 07:00AM	Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference (GlobeNewswire)
May-01-24 10:01AM	Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know (Zacks)
07:00AM	Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? (Zacks)
Mar-26-24 09:53AM	WuXi Biologics Reports Solid 2023 Annual Results (PR Newswire)
Mar-20-24 07:00AM	Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-06-24 11:56PM	Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) (GuruFocus.com) -5.62%
Mar-05-24 01:50PM	Amicus Therapeutics Stock Sees RS Rating Improve To 74 (Investor's Business Daily)
Mar-01-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 (GlobeNewswire)
Feb-29-24 11:25AM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:23AM	Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates (Zacks)
Feb-28-24 11:49PM	Q4 2023 Amicus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.50%
08:20AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:32AM	Amicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ... (GuruFocus.com)
07:00AM	Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-15-24 07:00AM	Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire) +6.22%
Feb-09-24 03:14PM	Amicus Therapeutics Stock Sees Improved Relative Strength Rating (Investor's Business Daily)
Feb-08-24 07:00AM	Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) at the 20th Annual WORLDSymposium (GlobeNewswire)
Feb-01-24 07:00AM	Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium 2024 (GlobeNewswire)
Jan-12-24 11:02PM	Amicus Therapeutics Inc Chief Accounting Officer Sells Company Shares (GuruFocus.com)
09:31AM	Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why (Zacks)
Jan-08-24 09:40AM	Amicus (FOLD) Issues Preliminary Revenue Results for FY23 (Zacks)
Jan-07-24 04:00PM	Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook (GlobeNewswire)
Jan-05-24 07:02PM	Amicus Therapeutics Inc President and CEO Bradley Campbell Sells 15,833 Shares (GuruFocus.com)
Jan-03-24 11:46AM	15 Best Growth Stocks to Buy Under $25 (Insider Monkey)
07:00AM	Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-23 09:01AM	Amicus Therapeutics Inc's Chief Development Officer Sells Shares (GuruFocus.com)
Dec-29-23 09:48AM	Amicus (FOLD) Banks on Galafold, Overdependence a Concern (Zacks)
07:01AM	Amicus Therapeutics Inc Chief Accounting Officer Sells Company Shares (GuruFocus.com)
Dec-24-23 06:17AM	Time to Pull the Trigger, Says Morgan Stanley About These 2 Healthcare Stocks (TipRanks)
Dec-21-23 05:01AM	Amicus Therapeutics Inc's Chief Development Officer Sells Shares (GuruFocus.com)
Dec-08-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report? (Zacks)
Dec-05-23 06:38AM	BIO names longtime Amicus head John Crowley as new CEO (BioPharma Dive)
06:00AM	Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO (GlobeNewswire)
05:30AM	He Designed Drugs to Save His Children. Now Hes Working to Save Biotech, Too. (The Wall Street Journal)
Nov-15-23 09:48AM	7 Stocks Most Likely to Follow in WeWorks Woeful Footsteps (InvestorPlace)
Nov-10-23 10:07AM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 01:02PM	Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated (Zacks) -12.19%
Nov-08-23 07:13AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-04-23 05:03AM	Insider Sell: Amicus Therapeutics Inc President and CEO Bradley Campbell Sells 11,700 Shares (GuruFocus.com)
Nov-02-23 10:00AM	Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Nov-01-23 10:01AM	Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023 (GlobeNewswire)
Oct-27-23 07:00AM	Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-08-23 07:00AM	This Rare Disease Pharma Is a Hidden Gem (TheStreet.com)
Oct-05-23 07:45PM	Stay Invested Through the Uncertainty: J.P. Morgan Says Stocks Could Reach New Highs Next Year Here Are 2 Names to Pounce on Now (TipRanks)
03:01AM	Insider Sell: Amicus Therapeutics Inc President & CEO Bradley Campbell Sells 11,700 Shares (GuruFocus.com)
Oct-03-23 07:00AM	Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023 (GlobeNewswire)
Oct-02-23 08:20AM	Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration (GlobeNewswire) -9.29%
Oct-01-23 08:30PM	WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease (PR Newswire)

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	President and CEO	Nov 06 '24	Option Exercise	12.28	7,901	97,024	894,555	Nov 07 05:49 PM
Campbell Bradley L	President and CEO	Nov 06 '24	Sale	12.50	7,901	98,800	886,654	Nov 07 05:49 PM
BRADLEY CAMPBELL	Director	Nov 06 '24	Proposed Sale	11.74	7,901	92,758		Nov 06 05:03 PM
Campbell Bradley L	President and CEO	Nov 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Nov 04 06:23 PM
Campbell Bradley L	President and CEO	Nov 01 '24	Sale	11.46	7,500	85,960	886,654	Nov 04 06:23 PM
BRADLEY CAMPBELL	Director	Nov 01 '24	Proposed Sale	11.42	7,500	85,650		Nov 01 04:49 PM
Campbell Bradley L	President and CEO	Oct 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Oct 04 04:05 PM
Campbell Bradley L	President and CEO	Oct 01 '24	Sale	10.60	7,500	79,492	886,654	Oct 04 04:05 PM
BRADLEY CAMPBELL	Director	Oct 01 '24	Proposed Sale	10.68	7,500	80,100		Oct 01 04:35 PM
Campbell Bradley L	President and CEO	Sep 03 '24	Option Exercise	8.61	7,500	64,575	894,154	Sep 05 05:01 PM
Campbell Bradley L	President and CEO	Sep 03 '24	Sale	11.71	7,500	87,798	886,654	Sep 05 05:01 PM
BRADLEY CAMPBELL	Director	Sep 03 '24	Proposed Sale	11.61	7,500	87,075		Sep 03 04:19 PM
Campbell Bradley L	President and CEO	Aug 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Aug 05 08:10 PM
Campbell Bradley L	President and CEO	Aug 01 '24	Sale	10.34	7,500	77,518	886,654	Aug 05 08:10 PM
BRADLEY CAMPBELL	Director	Aug 01 '24	Proposed Sale	10.31	7,500	77,325		Aug 01 04:25 PM
Campbell Bradley L	President and CEO	Jul 05 '24	Option Exercise	8.61	6,100	52,521	892,754	Jul 09 05:01 PM
Campbell Bradley L	President and CEO	Jul 05 '24	Sale	10.00	6,100	61,029	886,654	Jul 09 05:01 PM
Campbell Bradley L	President and CEO	Jul 01 '24	Option Exercise	8.61	1,400	12,054	888,054	Jul 03 04:22 PM
Campbell Bradley L	President and CEO	Jul 01 '24	Sale	10.00	1,400	14,003	886,654	Jul 03 04:22 PM
Campbell Bradley L	President and CEO	Jun 03 '24	Option Exercise	8.61	7,500	64,575	894,154	Jun 05 04:35 PM
Campbell Bradley L	President and CEO	Jun 03 '24	Sale	10.00	7,500	75,000	886,654	Jun 05 04:35 PM
Campbell Bradley L	President and CEO	May 01 '24	Option Exercise	8.61	7,500	64,575	894,154	May 03 05:21 PM
Campbell Bradley L	President and CEO	May 01 '24	Sale	10.07	7,500	75,524	886,654	May 03 05:21 PM
Campbell Bradley L	President and CEO	Apr 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Apr 03 06:14 PM
Campbell Bradley L	President and CEO	Apr 01 '24	Sale	11.67	7,500	87,496	886,654	Apr 03 06:14 PM
SBLENDORIO GLENN	Director	Mar 07 '24	Option Exercise	2.80	15,000	42,000	83,596	Mar 11 05:36 PM
RAAB MICHAEL	Director	Mar 05 '24	Option Exercise	2.80	15,000	42,000	83,596	Mar 06 05:22 PM
MCGLYNN MARGARET G	Director	Mar 04 '24	Option Exercise	2.80	7,500	21,000	66,789	Mar 06 05:21 PM
MCGLYNN MARGARET G	Director	Mar 05 '24	Option Exercise	2.80	7,500	21,000	66,789	Mar 06 05:21 PM
MCGLYNN MARGARET G	Director	Mar 05 '24	Sale	13.40	7,500	100,500	59,289	Mar 06 05:21 PM
MCGLYNN MARGARET G	Director	Mar 04 '24	Sale	13.29	7,500	99,675	59,289	Mar 06 05:21 PM
Campbell Bradley L	President and CEO	Mar 01 '24	Option Exercise	10.54	15,833	166,904	887,052	Mar 05 05:14 PM
Campbell Bradley L	President and CEO	Mar 01 '24	Sale	13.14	15,833	208,017	871,219	Mar 05 05:14 PM
Crowley John F	Executive Chairman	Mar 01 '24	Sale	13.35	29,181	389,543	573,478	Mar 05 05:14 PM
Crowley John F	Executive Chairman	Feb 15 '24	Sale	13.81	31,614	436,551	697,628	Feb 20 05:23 PM
Campbell Bradley L	President and CEO	Feb 15 '24	Sale	14.00	4,167	58,338	871,219	Feb 20 05:21 PM
Clark David Michael	Chief People Officer	Feb 15 '24	Sale	14.00	4,427	61,978	253,664	Feb 20 05:20 PM
Rosenberg Ellen	Chief Legal Officer	Feb 07 '24	Option Exercise	5.16	29,600	152,736	397,254	Feb 08 04:40 PM
Rosenberg Ellen	Chief Legal Officer	Feb 06 '24	Option Exercise	5.16	400	2,064	368,054	Feb 08 04:40 PM
Rosenberg Ellen	Chief Legal Officer	Feb 07 '24	Sale	13.00	29,600	384,818	367,654	Feb 08 04:40 PM
Rosenberg Ellen	Chief Legal Officer	Feb 06 '24	Sale	13.00	400	5,200	367,654	Feb 08 04:40 PM
Campbell Bradley L	President and CEO	Feb 01 '24	Option Exercise	10.54	15,833	166,904	891,219	Feb 05 07:22 PM
Campbell Bradley L	President and CEO	Feb 01 '24	Sale	12.56	15,833	198,858	875,386	Feb 05 07:22 PM
Crowley John F	Executive Chairman	Feb 01 '24	Sale	12.62	31,614	398,918	750,838	Feb 05 07:22 PM
Crowley John F	Executive Chairman	Jan 22 '24	Sale	12.36	55,327	683,958	782,452	Jan 24 05:20 PM
Crowley John F	Executive Chairman	Jan 16 '24	Sale	12.78	31,614	404,106	837,779	Jan 18 05:09 PM
Crowley John F	Executive Chairman	Jan 10 '24	Sale	13.65	31,614	431,452	869,393	Jan 11 06:33 PM
Clark David Michael	Chief People Officer	Jan 08 '24	Sale	14.00	8,726	122,164	268,089	Jan 09 06:08 PM
Clark David Michael	Chief People Officer	Jan 09 '24	Sale	14.00	1,384	19,376	266,705	Jan 09 06:08 PM
Prout Samantha	Chief Accounting Officer	Jan 08 '24	Sale	14.00	30,767	430,827	82,290	Jan 09 06:07 PM
Prout Samantha	Chief Accounting Officer	Jan 09 '24	Sale	14.00	1,337	18,718	80,953	Jan 09 06:07 PM
Campbell Bradley L	President and CEO	Jan 02 '24	Option Exercise	10.54	15,833	166,904	956,138	Jan 04 06:35 PM
Campbell Bradley L	President and CEO	Jan 02 '24	Sale	14.23	15,833	225,380	947,805	Jan 04 06:35 PM
Rosenberg Ellen	Chief Legal Officer	Jan 02 '24	Option Exercise	5.16	30,000	154,800	372,285	Jan 04 06:24 PM
Rosenberg Ellen	Chief Legal Officer	Jan 02 '24	Sale	14.21	30,000	426,219	342,285	Jan 04 06:24 PM
Castelli Jeff	Chief Development Officer	Dec 28 '23	Sale	14.52	17,421	252,902	340,661	Dec 29 05:18 PM
Prout Samantha	Chief Accounting Officer	Dec 26 '23	Sale	14.00	7,659	107,228	121,912	Dec 28 05:09 PM
Rosenberg Ellen	Chief Legal Officer	Dec 26 '23	Option Exercise	5.16	30,000	154,800	372,285	Dec 28 05:08 PM
Rosenberg Ellen	Chief Legal Officer	Dec 27 '23	Option Exercise	5.16	5,000	25,800	347,285	Dec 28 05:08 PM
Rosenberg Ellen	Chief Legal Officer	Dec 26 '23	Sale	14.00	30,000	420,084	342,285	Dec 28 05:08 PM
Rosenberg Ellen	Chief Legal Officer	Dec 27 '23	Sale	14.07	5,000	70,327	342,285	Dec 28 05:08 PM
Castelli Jeff	Chief Development Officer	Dec 19 '23	Sale	13.25	17,500	231,875	359,736	Dec 20 04:41 PM
Castelli Jeff	Chief Development Officer	Dec 20 '23	Sale	13.10	1,654	21,667	358,082	Dec 20 04:41 PM
Crowley John F	Executive Chairman	Dec 15 '23	Sale	12.66	6,043	76,516	877,748	Dec 19 05:55 PM
Campbell Bradley L	President and CEO	Dec 01 '23	Option Exercise	2.94	11,702	34,404	803,863	Dec 05 05:07 PM
Campbell Bradley L	President and CEO	Dec 01 '23	Sale	11.08	11,702	129,693	792,161	Dec 05 05:07 PM
Crowley John F	Executive Chairman	Dec 01 '23	Sale	11.08	6,043	66,956	883,791	Dec 05 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FOLD

Amicus Therapeutics Inc

Upgrade your FINVIZ experience